Situation In the early 2010s, the United Arab Emirates (UAE) was investing heavily in healthcare, yet affordability remained a barrier for some patients seeking access to high quality treatments. Age related macular degeneration (AMD) and multiple sclerosis (MS) were two examples where effective therapies were available, but the cost of sustained treatment could put them … Continued
Situation For patients living with chronic conditions, access to treatment can be shaped as much by financial circumstances as by the availability of the medicine itself. In countries with limited healthcare infrastructure and significant financial disparities, the cost of treatment can prevent patients from starting or completing their prescribed therapy. These challenges are particularly important … Continued
Situation A global pharmaceutical company wanted to better understand the impact of its patient access programs, which Axios had been implementing across markets for several years. While the company knew how many patients its programs had reached, it wanted to understand the bigger picture. How many patients could potentially benefit from treatment, and what proportion … Continued
“Rare” can be misleading when it comes to rare disease. The term can evoke a handful of cases scattered around the world, or conditions so unusual that they barely register as a public health concern. The numbers tell a different story. According to Rare Diseases International, between 6,000 and 8,000 known rare diseases affect an … Continued
Traditional market-access frameworks may not fully reflect the economic realities of LMICs, where affordability and out-of-pocket costs can create significant barriers to treatment. Traditional market-access frameworks may not fully reflect the economic realities of LMICs, where affordability and out-of-pocket costs can create significant barriers to treatment. Axios highlighted how affordability segmentation tcan be used effectively … Continued
Earlier this month, Dr. Joseph Saba joined the “Priorities and Challenges in Polish and European Drug Policy 2025” Conference to share insights on advancing access to medicines in a world shaped by growing discord and policy uncertainty. “Me-first” trade policies could unravel decades of progress on medicine access. As geopolitical and trade pressures reshape medicine … Continued
What Happens When Financial Support Isn’t Enough to Start Treatment? Financial assistance is often viewed as the final step in making treatment accessible. Once the cost barrier has been addressed, it can be tempting to assume the patient will simply begin treatment. In practice, there can be another gap between being approved for support and … Continued
What a New Study Reveals About Chronic Disease Adherence A newly diagnosed patient rarely intends to fall off treatment. Someone diagnosed with heart failure or asthma typically starts out committed, follows the plan, and shows up to appointments. Then, a few months in, many simply stop. The question worth asking isn’t whether that happens; it’s … Continued
When Data Concerns Become Barriers to Access Access does not begin when a patient receives a medicine or starts treatment. It begins much earlier—when a patient decides whether they feel comfortable engaging with the healthcare system, sharing the information needed to support their care, and participating in the services available to them. That makes trust … Continued
Patients can face healthcare access barriers even when they have the means to pay for treatment over time. In this discussion, Axios leaders explore how cash flow challenges can delay treatment and introduce On-Time Access (OTA), a new model designed to help eligible patients access treatment when they need it. The conversation also examines innovative … Continued